arrow
M

Marcela A. Ferrada

university of maryland school of medicine
H指数:24
被引数:3,433

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

开发用于评估VEXAS综合征(VEXAS-DAI)疾病活动度的指数

2026-09-080
OAAI
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

PAXIS:一项随机、双盲、安慰剂对照、剂量探索的II期研究(第一部分),随后进行开放标签期(第二部分),以评估Pacritinib在VEXAS综合征患者中的有效性和安全性

2026-02-270
OAAI
Establishing a consensus definition of VEXAS flare for clinical research

建立VEXAS flare的临床研究共识定义

2025-12-010
PRE
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

美国风湿病学会关于VEXAS诊断与管理的指南声明,由国际VEXAS工作组专家委员会制定

2025-08-110
OAAI
Opportunistic Infections, Mortality Risk, and Prevention Strategies in Patients With Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome
2024-07-234
OA
Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population
2023-01-24103
OA
Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS
2021-08-31142
PREAI
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1
2021-08-24147
OA
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease
2020-12-31659
OAAI